Lab Sciences
Top stories summarized by our editors
8/16/2019

University of North Carolina Health Care investigators have developed a novel method to increase the potency of antibiotics and their capability to eradicate disease-causing pathogens in response to the global health threat of antibiotic resistance. Details of the study were published in the journal Cell Chemical Biology.

Full Story:
News Medical
8/16/2019

Genetic variations in the HLA and IL-10 genes are associated with higher risk of developing inhibitors to factor VIII therapy for hemophilia A, according to a study in the journal PLOS ONE. The findings were based on data from more than 600 patients in Germany.

Full Story:
Hemophilia News Today
8/16/2019

A study in the journal ACS Sensors details a method for monitoring sickle hemoglobin that uses a microfluidics-based electrical impedance sensor rather than biochemical markers or microscopic imaging.

8/16/2019

The chimeric antigen receptor T-cell therapy tisagenlecleucel, or Kymriah, demonstrated measurable in vivo expansion among patients with relapsed or refractory diffuse large B-cell lymphoma who had no measurable disease following bridging chemotherapy. The study in the journal Blood Advances was based on a subset of data from a clinical trial.

8/15/2019

Temple University spinout Renovacor gained $11 million from a Series A funding round, which the company will use to advance development of a novel gene replacement therapy targeting a subset of patients with heart failure who have dilated cardiomyopathy.

8/15/2019

Investigators found that the combination therapy of Celgene's Revlimid, or lenalidomide, and dexamethasone could prove effective as a treatment for relapsed or refractory multiple myeloma if patients experience a partial response after undergoing their first treatment cycle, according to the journal Clinical Lymphoma, Myeloma & Leukemia. Study authors do note, though, that triple-drug Revlimid-based therapies should still be the primary treatment for this patient population.

Full Story:
Myeloma Research News
8/15/2019

The World Health Organization said Burundi has begun an Ebola virus vaccination campaign for health care workers using Merck's rVSV-ZEBOV at a border crossing with the Democratic Republic of Congo.

8/14/2019

National Institute of Allergy and Infectious Disease Director Dr. Anthony Fauci and clinical associate Dr. Andrea Lerner wrote in the Journal of the American Medical Association that growing rates of injection drug use threatens to increase rates of new HIV diagnoses, and rural areas are particularly vulnerable due to a lack of prevention and treatment resources. "This lack of harm-reduction services threatens to reverse decades of progress and recapitulate the devastating effects that IDU-related transmissions had during the earlier years of the HIV epidemic in the United States," they write.

8/14/2019

A prospective clinical trial found low rates of major bleeding and arterial thromboembolism among patients with atrial fibrillation whose direct oral anticoagulant therapy was managed before and after elective surgical procedures, researchers reported in JAMA Internal Medicine. Depending on the anticoagulant therapy patients were taking, rates of major bleeding in the 3,007-person study ranged from 0.90% to
1.85%.

Full Story:
2 Minute Medicine
8/13/2019

Investigators conducted a systemic review of nine studies on incidences of central line-associated bloodstream infections, and findings indicated that CLABSIs were consistently underestimated within publicly reported rates. Details of the study were reported in the journal Infection Control & Hospital Epidemiology.